directors and officers


Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host immune response to infection. It is not a specific disease but a syndrome encompassing a complex over-response by the patient that is still the subject of much investigation [1]. Sepsis has become an increasing public health concern as a leading cause of morbidity and mortality worldwide [2,3]. Recent estimates suggest there are nearly 50 million cases of sepsis cases globally each year [2] resulting in 8-11 million deaths [4,5]. Despite minor advancements in treatment, the search for more effective treatments for sepsis remains elusive. Of more than 100 clinical trials in the past 3 decades, only a handful of studies showed any significant improvement on mortality [6,7]. With the exception of the arrival of several new antibiotics, no new therapy products have been approved [8,9].

Enhanced MSC Cell Therapy

Northern Therapeutics has developed a powerful new platform using human MSC (Mesenchymal Stem or Stromal Cells). MSCs are a type of adult somatic stem cells that can be delivered as an “off-the-shelf” product to any patient without fear of rejection. Northern Therapeutics has enhanced these cells so that they can produce special proteins to treat dangerous diseases.

Amethyst Clinical Trial

The “Advanced Mesenchymal Enhanced cell THerapY for SepTic patients” (AMETHYST, NCT04961658) is a first-in-human dose-escalation study to assess the safety of allogeneic mesenchymal stem cells engineered to express two human genes linked to sepsis survival.
The purpose of this early phase trial is to establish the safety of this enhanced MSC product (GEM00220) in participants with septic shock. Northern Therapeutics is actively recruiting patients in the Amethyst trial.

If you want to learn more about Sepsis cell therapy and the Amethyst trial, contact Northern Therapeutics at +1 343 291 1197 / email: adminhr@northernther.com.